US and 5EU Rheumatoid Arthritis Drugs Market Analysis and Forecasts to 2023

DALLAS, March 19, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "PharmaPoint: Rheumatoid Arthritis - US and 5EU Drug Forecast and Market Analysis to 2023" report provides information on the key drugs in the US, 5EU, Australia & Japan including product description, safety and efficacy profiles as well as a SWOT analysis.

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

The report "PharmaPoint: Rheumatoid Arthritis - US Drug Forecast and Market Analysis to 2023" provides detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis. This market will be driven heavily by the increased population of RA patients, due, in part, to the growing overall population, an increased life expectancy, and increased awareness of RA, which requires early diagnosis and treatment. In addition, changes in healthcare resulting from implementation of the Affordable Care Act (ACA) will mean that access to physicians and pharmaceuticals will increase over the forecast period. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=312769 . (This is a premium report priced at US$4995 for a single user License.)

The report "PharmaPoint: Rheumatoid Arthritis - 5EU Drug Forecast and Market Analysis to 2023" provides detailed information on the key drugs in the 5EU including product description, safety and efficacy profiles as well as a SWOT analysis. The key drivers of this growth include an increase in the RA patient population, higher drug prices in Germany as compared with the other four major EU countries, and ample opportunities within the biosimilars market. However, the Italian government is implementing austerity measures to keep healthcare costs low, and is expected to promote the use of less expensive treatment alternatives. However, the growth of the RA market in Spain will be hindered by the implementation of austerity measures, which aim to cut healthcare costs and will thus limit the prescribing of biologic agents. The key drivers of this growth include the increasing RA patient population and the universal healthcare system, which allows all RA patients access to healthcare, while austerity measures aimed at cutting healthcare costs will serve as a barrier to market growth. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=312770 . (This is a premium report priced at US$6995 for a single user License.)

This reports discussed major brand product profiles include Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab), Simponi (golimumab), Cimzia (certolizumab pegol), Orencia (abatacept), Actemra/RoActemra (tocilizumab), Rituxan/MabThera (rituximab), Inflectra/Remsima (infliximab biosimilar), Methotrexate (Numerous Brands).

The report also provides promising drugs in clinical development that includes Sarilumab, Sirukumab, Clazakizumab, Cosentyx (secukinumab), Tregalizumab, Mavrilimumab, Baricitinib, Peficitinib, Decernotinib, Filgotinib, Masitinib and RAVAX.

Explore more reports of Arthritis Drugs at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/arthritis-drugs .

Related reports on Arthritis Drugs Market:

PharmaPoint: Rheumatoid Arthritis - Current and Future Players 

The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Rheumatoid Arthritis Market. The report identifies and analyses the key companies shaping and driving the global Rheumatoid Arthritis market. The report provides insight into the competitive Rheumatoid Arthritis landscape, including new companies entering the market. Complete report is available at http://www.rnrmarketresearch.com/pharmapoint-rheumatoid-arthritis-current-and-future-players-market-report.html .

PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis to 2023 

The drivers of growth in this market include the increasing RA patient population and the universal healthcare system, as well as the use of technology to connect patients with physicians and speed the process of diagnosis and treatment. Barriers to the growth of the market include government measures to cut healthcare spending, similar to the austerity measures implemented in the 5EU. In the RA market in Australia, there are a number of different treatment options available, similar to the 7MM. Complete report is available at http://www.rnrmarketresearch.com/pharmapoint-rheumatoid-arthritis-australia-drug-forecast-and-market-analysis-to-2023-market-report.html .

PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis to 2023 

The drivers of sales in this market include the aging population and the increasing prevalence of RA, as well as the universal healthcare system, which provides ease of access to physicians and specialists. Barriers to the growth of this market include the approval process for drugs in Japan, which requires trials to be conducted in Japanese populations, and the lag time between the approval and launch of drugs. Biosimilars are expected to launch in the RA market in Japan during the forecast period. Complete report is available at http://www.rnrmarketresearch.com/pharmapoint-rheumatoid-arthritis-japan-drug-forecast-and-market-analysis-to-2023-market-report.html .

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis Event-Driven Update 

The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market. The report is an essential source of information and analysis on the global RA market. Complete report is available at http://www.rnrmarketresearch.com/pharmapoint-rheumatoid-arthritis-global-drug-forecast-and-market-analysis-event-driven-update-market-report.html .

About Us:

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales@rnrmarketresearch.com